Canterbury DHB


Management of Relapse or Refractory Patients

Patients who relapse from AML17, can be entered into the treatment arm for high risk patients in AML19.

Key Questions for relapse/refractory patients:

If remission was obtained:

What does the patient want?

These considerations will dictate management and vary from patient to patient.

Check to see if there is a relapse/refractory trial to offer the patient. See the Clinical Trials page on the Intranet or phone the Clinical Trials Co-ordinator (ext: 80377).

In This Section

Idarubicin / Cytarabine Protocol

About this Canterbury DHB document (4291):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4291